Previous 10 | Next 10 |
home / stock / esaly / esaly news
Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...
Despite the Centers for Medicare & Medicaid Services' (CMS) decision on April 7 to severely limit coverage of Biogen's (NASDAQ:BIIB) Aduhelm (aducanumab) for Alzheimer's disease, other drugmakers are forging ahead with their candidates for the condition. On Friday, Eisai (OTCPK:ESALY) sai...
Eisai (OTCPK:ESALY) (OTCPK:ESALF) expects to complete the rolling submission for its lecanemab’s Biologics License Application (BLA) to the FDA under the regulator’s accelerated approval pathway in 1Q fiscal 2022. The Japanese drugmaker is advancing the experimental Alzheimer...
In late February, the combo of Merck 's (NYSE: MRK) Keytruda and a drug that Merck co-owns with Eisai (OTC: ESALY) , known as Lenvima, received its second regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW). The drug pairing was given the green...
Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease PR Newswire Research collaboration will test novel algorithm's effectiveness o...
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business TOKYO, Apr 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares...
Biogen (NASDAQ:BIIB) said it submitted the final study protocol to the U.S. Food and Drug Administration for a confirmatory phase 4 ENVISION trial of its Alzheimer’s disease (AD) drug Aduhelm, developed with Eisai (OTCPK:ESALF) (OTCPK:ESALY). The company said the co...
Following a sharp decline, the clinical-stage pharma company, Amylyx (NASDAQ:AMLX -41.3%) pared losses after Evercore ISI issued favorable views on the briefing documents released by the U.S. regulators on the company’s candidate for amyotrophic lateral sclerosis, AMX0035. Ahead of an ...
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor TOKYO, Mar 28, 2022 - (JCN Newswire) - Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca (Gene...
The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gilead Sciences (NASDAQ:GILD), Galapagos (NASDAQ:GLPG) and Eisai's (OTCPK:ESALF) drug Jyseleca (filgotinib) to treat patients with moderate-to-severe active ulcerative colitis (UC), an inflammatory bowel diseas...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...